drugset / Trial / NCT02256813

Study to Evaluate the Effect of Multiple Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Warfarin, Omeprazole, Caffeine, and Dextromethorphan in Healthy Male Volunteers

NCT02256813

Phase 1 Completed 20 enrolled Boehringer Ingelheim
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The study aimed to investigate the effect of BIRT 2584 XX and its metabolite BI 610100 on the Pharmacokinetics (PK) of five probe substrates for cytochrome P450 isozymes. The substrates used to monitor enzyme activity were oral warfarin (for CYP2C9), oral omeprazole (for CYP2C19), oral dextromethorphan (for CYP2D6), oral caffeine (for CYP1A2) and intravenous midazolam (for hepatic CYP3A)

Timeline

Start
2005-09
Primary completion
2005-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject BIRT 2584 XX Unknown 500 mg
Subject Caffeine Small molecule Oral
Subject Dextromethorphan Unknown Oral
Subject Midazolam Small molecule Intravenous
Subject Omeprazole Other / unclassified Oral
Subject Warfarin Small molecule Oral
Background Vitamin K Unknown

Indications

No indication recorded.